Application | Comment | Organism |
---|---|---|
drug development | CBR1 inhibition can improve the therapeutic response to doxorubicin and reduce its side effects | Homo sapiens |
Cloned (Comment) | Organism |
---|---|
CBR1 expressed as histidine-tagged protein | Homo sapiens |
CBR3 expressed as histidine-tagged protein | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
4-amino-1-tert-butyl-3-(2-hydroxyphenyl)pyrazolo[3,4-d]pyrimidine | - |
Homo sapiens |
KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|
0.132 | - |
doxorubicin | in stomach | Homo sapiens | |
0.134 | - |
doxorubicin | in kidney | Homo sapiens | |
0.14 | - |
doxorubicin | in colon | Homo sapiens | |
0.163 | - |
doxorubicin | in liver | Homo sapiens | |
0.167 | - |
doxorubicin | purified enzyme | Homo sapiens | |
0.231 | - |
doxorubicin | in lung | Homo sapiens | |
0.239 | - |
doxorubicin | in heart | Homo sapiens | |
0.244 | - |
doxorubicin | in skeletal muscle | Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
cytosol | - |
Homo sapiens | 5829 | - |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | P16152 | - |
- |
Purification (Comment) | Organism |
---|---|
- |
Homo sapiens |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
colon | - |
Homo sapiens | - |
colon | low expression of CBR3 | Homo sapiens | - |
heart | - |
Homo sapiens | - |
heart | low expression of CBR3 | Homo sapiens | - |
kidney | - |
Homo sapiens | - |
kidney | low expression of CBR3 | Homo sapiens | - |
liver | CBR1 is prominently expressed in the liver | Homo sapiens | - |
liver | low expression of CBR3 | Homo sapiens | - |
lung | - |
Homo sapiens | - |
lung | low expression of CBR3 | Homo sapiens | - |
skeletal muscle | - |
Homo sapiens | - |
skeletal muscle | low expression of CBR3 | Homo sapiens | - |
stomach | - |
Homo sapiens | - |
stomach | low expression of CBR3 | Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
9,10-phenanthrenequinone + NADPH + H+ | - |
Homo sapiens | ? + NADP+ | - |
? | |
doxorubicin + NADPH + H+ | CBR1 is a predominant hepatic doxorubicin reductase | Homo sapiens | doxorubicinol + NADP+ | - |
? | |
menadione + NADPH + H+ | - |
Homo sapiens | ? + NADP+ | - |
? | |
additional information | no doxorubicin or menadione reduction is catalyzed by CBR3 | Homo sapiens | ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
carbonyl reductase 1 | - |
Homo sapiens |
CBR1 | - |
Homo sapiens |
CBR3 | - |
Homo sapiens |
Turnover Number Minimum [1/s] | Turnover Number Maximum [1/s] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|
0.0103 | - |
doxorubicin | - |
Homo sapiens |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
NADPH | - |
Homo sapiens |
Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|
0.0105 | - |
4-amino-1-tert-butyl-3-(2-hydroxyphenyl)pyrazolo[3,4-d]pyrimidine | for doxorubicin metabolism | Homo sapiens |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.0013 | - |
for menadione metabolism | Homo sapiens | 4-amino-1-tert-butyl-3-(2-hydroxyphenyl)pyrazolo[3,4-d]pyrimidine |